- ICH GCP
- Amerikanska kliniska prövningsregistret
- Klinisk prövning NCT07439653
En studie av TORL-5-700 vid återfallande/refraktär non-Hodgkins lymfom
En fas 1/2, först-på-människa, öppen, multicenterstudie av TORL-5-700 som monoterapi och i kombination för deltagare med återfallande eller refraktär Non-Hodgkin lymfom
A Phase 1/2 study to evaluate safety, tolerability, and anticancer activity of TORL-5-700 as a monotherapy and in combination in R/R NHL
Studieöversikt
Status
Studietyp
Inskrivning (Beräknad)
Fas
- Fas 2
- Fas 1
Kontakter och platser
Studiekontakt
- Namn: Eric Park, M.D.
- Telefonnummer: (310) 598-5969
- E-post: eric.park@torlbio.com
Studieorter
-
-
California
-
Fullerton, California, Förenta staterna, 92835
- Rekrytering
- Providence Medical Foundation
-
Los Alamitos, California, Förenta staterna, 90720
- Rekrytering
- Cancer and Blood Specialty Clinic, Los Alamitos
-
Santa Monica, California, Förenta staterna, 90404
- Rekrytering
- UCLA
-
Stanford, California, Förenta staterna, 94305
- Rekrytering
- Stanford University
-
-
Florida
-
Miami, Florida, Förenta staterna, 33136
- Rekrytering
- University of California Miami, Sylvester Comprehensive Cancer Center
-
-
Iowa
-
Iowa City, Iowa, Förenta staterna, 52242
- Rekrytering
- University of Iowa Health Care
-
-
Kansas
-
Wichita, Kansas, Förenta staterna, 67214
- Rekrytering
- Cancer Center of Kansas, Wichita
-
-
Tennessee
-
Nashville, Tennessee, Förenta staterna, 37203
- Rekrytering
- Sarah Cannon Research Institute
-
-
Texas
-
Dallas, Texas, Förenta staterna, 75390
- Rekrytering
- University of Texas Southwestern Medical Center
-
-
Deltagandekriterier
Urvalskriterier
Åldrar som är berättigade till studier
Tar emot friska volontärer
Kön som är behöriga för studier
Beskrivning
Inclusion Criteria:
- Confirmed B-NHL, including but not limited to de novo DLBCL; FL, Grades 1 to 3A; MCL; transformed lymphoma (tFL, RT) and FL Grade 3B; MZL and MALT.
- Eastern Cooperative Oncology Group (ECOG) performance status less than or equal to 2.
- At least 1 measurable lesion per Lugano criteria.
- Tumor tissue is available.
- Adequate organ function
Exclusion Criteria:
- T-cell lymphoma
- CLL or SL
- Burkitt lymphoma and high-grade B-cell lymphoma
- CNS involvement
- Peripheral neuropathy > Grade 2
- Uncontrolled medical conditions
- Viral infections
Studieplan
Hur är studien utformad?
Designdetaljer
- Primärt syfte: Behandling
- Tilldelning: Icke-randomiserad
- Interventionsmodell: Sekventiell tilldelning
- Maskning: Ingen (Open Label)
Vapen och interventioner
Deltagargrupp / Arm |
Intervention / Behandling |
|---|---|
|
Experimentell: Part 1: Monotherapy Dose Escalation
TORL-5-700 Administered once every three weeks |
Part 1: Monotherapy Dose Escalation - TORL-5-700 Administered once every three weeks |
|
Experimentell: Part 2: Monotherapy Expansion
TORL-5-700 at MTD/RP2D Administered once every three weeks |
Part 2: Monotherapy Expansion - TORL-5-700 at Maximum tolerated Dose (MTD)/Recommended Phase 2 Dose (RP2D) Administered once every three weeks |
|
Experimentell: Part 3: Combination Evaluation
TORL-5-700 at MTD/RP2D Administered once every three weeks in combination with another agent |
Part 3: Combination Evaluation - TORL-5-700 at MTD/RP2D administered every three weeks in combination with another agent |
Vad mäter studien?
Primära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Evaluate the safety of TORL-5-700 as a monotherapy
Tidsram: though study completion, an average of 2.5 years
|
Assessment of adverse events according to NCI-CTCAE Version 5.0 |
though study completion, an average of 2.5 years
|
|
Assess the antitumor activity of TORL-5-700 as monotherapy
Tidsram: though study completion, an average of 2.5 years
|
Assess the antitumor activity of TORL-5-700 using Cheson (2014) disease grading criteria |
though study completion, an average of 2.5 years
|
|
Evaluate the safety of TORL-5-700 in combination with other agents
Tidsram: though study completion, an average of 2.5 years
|
Assessment of adverse events according to NCI-CTCAE Version 5.0 |
though study completion, an average of 2.5 years
|
|
Determine the Maximum Tolerated Dose (MTD)
Tidsram: 21 days from the start of treatment
|
Determine the MTD by assessing Protocol defined Dose Limiting Toxicities (DLT) |
21 days from the start of treatment
|
|
Determine the Recommended Phase 2 Dose (RP2D)
Tidsram: 21 days from the start of treatment
|
Determine the RP2D by assessing Protocol defined Dose Limiting Toxicities |
21 days from the start of treatment
|
Sekundära resultatmått
Resultatmått |
Åtgärdsbeskrivning |
Tidsram |
|---|---|---|
|
Maximum Serum Concentration of TORL-5-700 (Cmax)
Tidsram: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Maximum Serum Concentration of TORL-5-700 (Cmax) in combination with other agents
Tidsram: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Terminal Half-life (t1/2) of Serum TORL-5-700
Tidsram: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Terminal Half-life (t1/2) of Serum TORL-5-700 in combination with other agents
Tidsram: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration
Tidsram: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Area under the Serum Concentration -Time curve for TORL-5-700 from the time of dosing to the last measurable concentration in combination with other agents
Tidsram: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Clearance (CL) of TORL-5-700
Tidsram: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Clearance (CL) of TORL-5-700 in combination with other agents
Tidsram: though end of study treatment, an average of 5 months
|
Pk assessment |
though end of study treatment, an average of 5 months
|
|
Volume of distribution of TORL-5-700
Tidsram: though end of study treatment, an average of 5 months
|
PK assessment |
though end of study treatment, an average of 5 months
|
|
Volume of distribution of TORL-5-700 in combination with other agents
Tidsram: though end of study treatment, an average of 5 months
|
PK assessment |
though end of study treatment, an average of 5 months
|
|
Immunogenicity of TORL-5-700
Tidsram: though end of study treatment, an average of 5 months
|
Immunogenicity will be measured by incidence of treatment emergent ADAs |
though end of study treatment, an average of 5 months
|
|
Immunogenicity of TORL-5-700 in combination with other agents
Tidsram: though end of study treatment, an average of 5 months
|
Immunogenicity will be measured by incidence of treatment emergent ADAs |
though end of study treatment, an average of 5 months
|
|
Assess the preliminary antitumor activity of TORL-5-700 in combination with other agents
Tidsram: though study completion, an average of 2.5 years
|
Assess the antitumor activity of TORL-5-700 in combination with other agents using Cheson (2014) disease grading criteria |
though study completion, an average of 2.5 years
|
Samarbetspartners och utredare
Sponsor
Studieavstämningsdatum
Studera stora datum
Studiestart (Faktisk)
Primärt slutförande (Beräknad)
Avslutad studie (Beräknad)
Studieregistreringsdatum
Först inskickad
Först inskickad som uppfyllde QC-kriterierna
Första postat (Faktisk)
Uppdateringar av studier
Senaste uppdatering publicerad (Faktisk)
Senaste inskickade uppdateringen som uppfyllde QC-kriterierna
Senast verifierad
Mer information
Termer relaterade till denna studie
Ytterligare relevanta MeSH-villkor
Andra studie-ID-nummer
- TORL5700-001
Plan för individuella deltagardata (IPD)
Planerar du att dela individuella deltagardata (IPD)?
Läkemedels- och apparatinformation, studiedokument
Studerar en amerikansk FDA-reglerad läkemedelsprodukt
Studerar en amerikansk FDA-reglerad produktprodukt
Denna information hämtades direkt från webbplatsen clinicaltrials.gov utan några ändringar. Om du har några önskemål om att ändra, ta bort eller uppdatera dina studieuppgifter, vänligen kontakta register@clinicaltrials.gov. Så snart en ändring har implementerats på clinicaltrials.gov, kommer denna att uppdateras automatiskt även på vår webbplats .